DelveInsight has launched a new report on Antibody-Mediated Rejection Epidemiology

 

About Antibody-Mediated Rejection

Antibody-mediated rejection (AMR)—or humoral rejection—after renal transplantation is a devastating event that inevitably led to allograft loss. AMR poses a significant and continued challenge for long term graft survival in kidney transplantation. In the continuum of allograft rejection, the development of antibodies plays a critical role, and antibodies are considered a major cause of allograft failure.

 

Antibody-Mediated Rejection Epidemiology

Antibody-mediated rejection (AMR) is a major cause of late kidney transplant failure. Although hyperacute (i.e. preformed antibody-mediated) rejection has been recognized since the 1960s, the role of antibodies in other forms of rejection was not clear until new diagnostic methods became available. The knowledge about the role of antibodies in allograft rejection, particularly in some forms of chronic allograft rejection, has been evolving rapidly over the last decade.

 

Important facts of Antibody-Mediated Rejection Epidemiology report

• The incidence tends to be higher (up to 40%) in pediatric and medication-nonadherent adult transplant patients, with the latter constituting nearly two-thirds of adult transplant patients by 12 years after transplantation. AMR incidence among presensitized patients is more than 20%.
• Acute AMR occurs in about 5–7% of all kidney transplants and is responsible for 20–48% of acute rejection episodes among presensitized positive crossmatch patients.

 

Download free sample copy of Antibody-Mediated Rejection Epidemiology report- https://www.delveinsight.com/sample-request/antibody-mediated-graft-rejection-epidemiology-forecast

 

Antibody-Mediated Rejection Epidemiology Segmentation

• Incident Population of Antibody-Mediated Rejection (AMR) in the 7MM [2017-2030]
• Type-specific Incident Population of Antibody-Mediated Rejection (AMR) in the 7MM [2017-2030]
• Treatable Cases of Antibody-Mediated Rejection (AMR) in the 7MM [2017-2030]
• Gender-specific Incident Population of Antibody-Mediated Rejection (AMR) in the 7MM [2017-2030]

 

Antibody-Mediated Rejection Prevalent Population

The incidence of acute and chronic AMR was 45% and 36% in patients with C1q+DSA. The study indicated that the presence of C1q+ DSA was associated with acute and chronic AMR. With respect to diagnosis and follow-up, sensitive biomarkers that reflect disease activity, also during smouldering disease, are needed.

 

Antibody-Mediated Rejection Epidemiology: Report Scope

• The Antibody-Mediated Graft Rejection report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Antibody-Mediated Graft Rejection Epidemiology Report and Model provide an overview of the risk factors and global trends of Antibody-Mediated Graft Rejection in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Antibody-Mediated Graft Rejection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Antibody-Mediated Graft Rejection
• The report provides the segmentation of the Antibody-Mediated Graft Rejection epidemiology

 

Following is the table of content of Antibody-Mediated Rejection epidemiology report

1. Key Insights 

2. Executive Summary of Antibody-Mediated Graft Rejection

3. Antibody-Mediated Graft Rejection: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Download free sample copy of Antibody-Mediated Rejection Epidemiology report- https://www.delveinsight.com/sample-request/antibody-mediated-graft-rejection-epidemiology-forecast

 

What are the important reasons to buy this report?

• Develop business strategies by understanding the trends shaping and driving the global Antibody-Mediated Graft Rejection market
• Quantify patient populations in the global Antibody-Mediated Graft Rejection market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Antibody-Mediated Graft Rejection therapeutics in each of the markets covered
• Understand the magnitude of Antibody-Mediated Graft Rejection population by its epidemiology
• The Antibody-Mediated Graft Rejection Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/